Ribo Life Science executes HK$9.30 million on-market repurchase of 186,600 H shares

Bulletin Express07-13

Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30 million, implying an average purchase price of approximately HK$49.85 per share.

The buy-back was carried out on the open market and all repurchased shares will be held as treasury stock. The mandate authorising such repurchases was granted at the company’s annual general meeting on 5 June 2026.

Management stated that the operation reflects confidence in the group’s business outlook and is intended to enhance shareholder value. Future repurchases may be undertaken subject to market conditions and compliance with relevant regulations.

The board advised investors to exercise caution when dealing in the company’s securities, noting that the scale and timing of any further buy-backs remain at its discretion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181401404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181401404","market":"us","top_or_hot":-1,"title":"Ribo Life Science executes HK$9.30 million on-market repurchase of 186,600 H shares","media":"Bulletin Express","content":"<p>Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30 million, implying an average purchase price of approximately HK$49.85 per share.</p>\n<p>The buy-back was carried out on the open market and all repurchased shares will be held as treasury stock. The mandate authorising such repurchases was granted at the company’s annual general meeting on 5 June 2026.</p>\n<p>Management stated that the operation reflects confidence in the group’s business outlook and is intended to enhance shareholder value. Future repurchases may be undertaken subject to market conditions and compliance with relevant regulations.</p>\n<p>The board advised investors to exercise caution when dealing in the company’s securities, noting that the scale and timing of any further buy-backs remain at its discretion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo Life Science executes HK$9.30 million on-market repurchase of 186,600 H shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo Life Science executes HK$9.30 million on-market repurchase of 186,600 H shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-13 22:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30 million, implying an average purchase price of approximately HK$49.85 per share.</p>\n<p>The buy-back was carried out on the open market and all repurchased shares will be held as treasury stock. The mandate authorising such repurchases was granted at the company’s annual general meeting on 5 June 2026.</p>\n<p>Management stated that the operation reflects confidence in the group’s business outlook and is intended to enhance shareholder value. Future repurchases may be undertaken subject to market conditions and compliance with relevant regulations.</p>\n<p>The board advised investors to exercise caution when dealing in the company’s securities, noting that the scale and timing of any further buy-backs remain at its discretion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1181401404","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181401404","pubTimestamp":1783951583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"日博生命科学于市场购回186,600股H股930万港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30 million, implying an average purchase price of approximately HK$49.85 per share.\nThe buy-back was carried out on the open market and all repurchased shares will be held as treasury stock. The mandate authorising such repurchases was granted at the company’s annual general meeting on 5 June 2026.\nManagement stated that the operation reflects confidence in the group’s business outlook and is intended to enhance shareholder value. Future repurchases may be undertaken subject to market conditions and compliance with relevant regulations.\nThe board advised investors to exercise caution when dealing in the company’s securities, noting that the scale and timing of any further buy-backs remain at its discretion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181401404","isCrawlerRequest":true}